The pharmacokinetics of valganciclovir prophylaxis in pediatric solid organ transplant patients at risk for Epstein-Barr virus disease

Antiviral prophylaxis with valganciclovir is used frequently in pediatric solid organ transplant patients to prevent Epstein-Barr virus (EBV)-induced infections and tissue-invasive disease including post-transplant lymphoproliferative disorder (PTLD). This approach is untested in clinical trials and...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical pharmacology: advances and applications 2010-01, Vol.2, p.1-7
Hauptverfasser:	Vezina, Heather E, Brundage, Richard C, Nevins, Thomas E, Balfour, Jr, Henry H
Format:	Artikel
Sprache:	eng
Schlagworte:	Epstein-Barr virus Original Research Pediatrics Pharmacokinetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!